tul.com.cnCrawled Nov 8, 2026
Federal Pharmaceutical provides health food products under its large health product category.
Federal Pharmaceutical focuses on innovation in drug research and development across its four business segments.
Federal Pharmaceutical produces raw drugs and intermediates as part of its pharmaceutical offerings.
Federal Pharmaceutical offers oral antibacterial drugs as part of its formulation products.
Federal Pharmaceuticals updates its research and development progress, covering pharmaceutical intermediates, APIs, formulations, biologics, and pet care across its four business segments.
Federal Pharmaceutical engages in drug research, development, production, and sales across four business segments: formulations, raw materials, biologics, and pet care.
Federal Pharmaceutical outlines its privacy protection policies.
Federal Pharmaceutical provides a legal disclaimer regarding its pharmaceutical research, development, production, and sales operations.
United Laboratories International Holdings (3933.HK) secures a **US$9 million** milestone payment from **Novo** for advancing **UBT251 Injection** into a **global Phase II clinical trial** targeting **type 2 diabetes (T2DM)**. The payment follows a voluntary announcement by the company on **23 September 2026**, after accounting for Danish withholding tax. This milestone marks progress in the drug’s clinical development pipeline under a collaboration with Novo.
Sep 2026新時空News article
The United Laboratories International Holdings Limited releases its earnings results for the half-year period ending June 30, 2026. The report outlines financial performance metrics for investors and stakeholders. Key details on revenue, expenses, and operational highlights are included in the disclosure.
Aug 2026MarketScreenerNews article
The United Laboratories International reports an **18% revenue decline** and **81.6% drop in net profit** in H1 2026, driven by market and policy challenges. Despite financial headwinds, the company maintains strong R&D investment and secures a **$15 million milestone payment** for its drug candidate **UBT251 Injection**. Gross margins and segment profits also decrease, while borrowings and finance costs rise.
Aug 2026TradingViewNews article
Novo Nordisk and United Laboratories report that their diabetes drug **UBT251** shows strong improvements in blood glucose control and weight reduction in a phase 2 clinical trial involving Chinese patients with type 2 diabetes. The trial results highlight the potential efficacy of the treatment in managing key symptoms of the condition. The collaboration between the two companies aims to advance UBT251 toward further development.
Mar 2026InvestorsHubNews article